Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma

Alexandar Tzankov,1 Cecile Meier,1 Petra Hirschmann,1 Philip Went,2 Stefano A. Pileri,3 and Stephan Dirnhofer1

1Institute of Pathology, University Hospital Basel, Switzerland; 2Institute of Pathology, Triemli Hospital, Zurich, Switzerland; 3Chair of Pathology and Unit of Hematopathology, Institute of Hematology and Clinical Oncology “L. and A. Seràgnoli”, University of Bologna, Italy


Supplementary Design and Methods

Design and Methods

Patients, treatment regimens, definition of response, relapse and treatment failures

HIV infection (n=5) and post-transplant settings (n=6) were not considered exclusion criteria. Treatment was either standard or consistent with the investigational protocols active during the time the patients were diagnosed; only 5 diffuse large B-cell lymphomas (DLBCL) patients were given rituximab. Complete disease remission was defined as absence of disease on laboratory, imaging and physical examinations for at least 3 months after cessation of the last treatment regimen. Disease relapses were defined as recurrences after remission. Minor tumor shrinkage, immediate progressive disease, and early relapses (within 3 months after cessation of the last treatment regimen) were considered failure to achieve complete remission. Death with/of disease and failure to achieve complete remission defined treatment failures.

Tissue microarray construction

One [marginal zone- (MZL), peripheral T-cell- (PTCL) and angioimmunoblastic T-cell lymphomas (AILT)], two [DLBCL from Innsbruck and Basel, follicular lymphomas (FL), small lymphocytic lymphomas/chronic lymphocytic leukemias (SLL/CLL) from Innsbruck, Burkitt lymphomas (BL), anaplastic large cell lymphomas (ALCL) and classical Hodgkin lymphomas (cHL) from Innsbruck and Basel] or three [primary mediastinal B-cell lymphomas (PMBCL), DLBCL from Bologna, SLL/CLL from Bologna and cHL from Bologna] cores from every sample were arrayed.

Immunohistochemical double stains

For double-stains on conventional slides from tonsils, heat-induced antigen retrieval in Tec buffer (pH8.0, from Biologo, Kronshagen, Germany) was performed for 20 minutes at 100°C and the slides incubated for 32 minutes at 37°C with the primary anti-FOXP3 antibody on an automated immunostainer using the streptavidin-biotin-peroxidase detection system with diaminobenzidine as chromogen (brown). A second incubation for 120 minutes at 37°C with the primary anti-CD4 (1:80, from Neomarkers, Fremont, CA, USA) or anti-CD25 antibody (1:100, from Neomarkers) was subsequently carried out using the streptavidin-biotin-peroxidase detection system with 3-amino-9-ethyl-carbazole as chromogen (red).

Results

Life status data

The mean observation period for the 515 B- and T-cell lymphoma patients with known follow-up data was 51 months (range 0.5-219, median 33 months). Within that period, 179 (35%) patients died with/of disease, 27 (5%) due to second malignancies, 26 (5%) of cardio-vascular events and 13 (2.5%) due to other causes (infections, trauma). The mean observation period for the 152 cHL patients with known follow-up data was 115 months (range 0.5-219, median 105 months). Within that period, 17 (11%) patients died with/of disease, 18 (12%) due to secondary malignancies, 8 (5%) of cardio-vascular events and 9 (6%) due to other causes (infections, trauma).

Correlations of FOXP3+ cell quantity with lymphoma phenotype and expression of cell cycle-regulators

There were no additional correlations of the amount of FOXP3+ cells with other known phenotypic characteristics in the studied entity collectives such as deregulated expression of cell cycle regulating proteins (p21, p27, p53, bcl-2, cyclin A, D1, D3, E, Mib-1), angiogenesis (CD34, COX2, VEGF-A, Flk-1, Flt-1) and expression of other lineage-, differentiation-associated- and viral antigens (bcl-6, CD2, CD3, CD4, CD5, CD8, CD10, CD15, CD20, CD30, CD44s, CD79a, CD117, CD138, FOXP1, MUM1, LMP-1, ZAP-70).
Comparison of the results for the prognostic molecular classification of our diffuse large B-cell lymphoma series according to the Hans’ algorithm using cut-off values of the variables as suggested in the original publication (upper) and those suggested by the ROC curves (lower).